Search
MK-8666
go.drugbank.com/drugs/DB14937InvestigationalMK-8666 is under investigation in clinical trial NCT01971554 (Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of MK-8666 in Participants With Type 2 Diabetes Mellitus (MK-8666-003)).
Gadopiclenol
go.drugbank.com/drugs/DB17084ApprovedInvestigational[L43817] In 2006, the use of GBCAs was associated with the development of nephrogenic systemic fibrosis (NSF), a rare disorder characterized by the thickening and hardening of skin and subcutaneous tissues … Gadopiclenol is a gadolinium-based contrast agent (GBCA) based on a pyclen macrocyclic structure.
Garadacimab
go.drugbank.com/drugs/DB15629Approved[L53283,A273998] Garadacimab received its first approval in Australia and the UK in January 2025, and has since been approved in a number of other jurisdictions, including the EU and Japan. … [A273993] In June 2025, garadacimab was approved by the US FDA for the prophylaxis of HAE episodes in patients ≥12 years of age.
Categories: Drugs Used in Hereditary AngioedemaMK-0773
go.drugbank.com/drugs/DB16244InvestigationalMK-0773 is under investigation in clinical trial NCT00529659 (A Study of the Safety and Efficacy of MK-0773 in Women With Sarcopenia (Loss of Muscle Mass)(mk-0773-005)).
Xanthinol
go.drugbank.com/drugs/DB09092ApprovedWithdrawn[L1079] Xaninthol is known to be a potent vasodilator that can easily pass through the cell membrane and once inside the cell it causes an increase in glucose metabolism resulting in an increased energy … [L1080] It was approved as a drug in 1998 in Canada and nowadays its status is cancelled post marketing.
Imetelstat
go.drugbank.com/drugs/DB14909ApprovedInvestigational[erythropoietin]), but primary resistance to these agents is frequent - the median response duration is 18 to 24 months, with most responders (70%) relapsing due to loss of sensitivity of erythroid progenitors … [A187838] Imetelstat received FDA approval in June 2024 for use in certain patients with MDS who have transfusion-dependent anemia and are unable to use ESAs.[L50883,L50888]
Vadadustat
go.drugbank.com/drugs/DB12255ApprovedInvestigational[A244145,A244155] It was first approved in Japan in 2020,[L50371] and in April 2023, it was approved by the EMA for the treatment of symptomatic anemia associated with CKD in adults on chronic maintenance … [L39610,L46936,L46951] Vadadustat was approved by the FDA in March 2024.[L50371]
Synonyms: N-(5-(3-Chlorophenyl)-3-hydroxypyridine-2-carbonyl)glycine, Glycine, N-((5-(3-chlorophenyl)-3-hydroxy-2-pyridinyl)carbonyl)-Tebipenem pivoxil
go.drugbank.com/drugs/DB16840Approvedresistant Gram-negative infections but had until now been available only intravenously, meaning patients with resistant complicated urinary tract infections generally required hospitalization, a PICC line … [L57980] Tebipenem pivoxil is the first oral carbapenem approved in the United States, creating an outpatient option for patients who have limited or no alternative oral therapy.
Lisuride
go.drugbank.com/drugs/DB00589ApprovedAn ergot derivative that acts as an agonist at dopamine D2 receptors (dopamine agonists). … It may also act as an antagonist at dopamine D1 receptors, and as an agonist at some serotonin receptors (serotonin agonists).
Synonyms: N'-((8alpha)-9,10-Didehydro-6-methylergolin-8-yl)-N,N-diethylureaNedocromil
go.drugbank.com/drugs/DB00716ApprovedA pyranoquinolone derivative that inhibits activation of inflammatory cells which are associated with asthma, including eosinophils, neutrophils, macrophages, mast cells, monocytes, and platelets.
Synonyms: 9-Ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano(3,2-g)chinolin-2,8-dicarbonsäure, 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano(3,2-g)quinoline-2,8-dicarboxylic acidProducts: Tilade Inhaler 2mg/aem